Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin by Heike Zimdahl et al.
ARTICLE
Influence of TCF7L2 gene variants on the therapeutic response
to the dipeptidylpeptidase-4 inhibitor linagliptin
Heike Zimdahl & Carina Ittrich & Ulrike Graefe-Mody &
Bernhard O. Boehm & Michael Mark &
Hans-Juergen Woerle & Klaus A. Dugi
Received: 22 November 2013 /Accepted: 29 April 2014 /Published online: 7 June 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis Individuals carrying variants of the tran-
scription factor 7-like 2 gene (TCF7L2) are at increased risk
for type 2 diabetes. These metabolic genetic risk factors have
been linked to diminished pancreatic islet-cell responsiveness
to incretins, thus pharmacological interventions aimed at am-
plifying endogenous incretin biology may be affected. How-
ever, clinical evidence from randomised controlled trials so far
is lacking. We investigated the influence of TCF7L2 risk
a l l e l e s on the response to t r ea tmen t wi th the
dipeptidylpeptidase-4 (DPP-4) inhibitor linagliptin from four
24 week, phase III, placebo-controlled trials.
Methods Pharmacogenomic samples and clinical data were
available from 961 patients with type 2 diabetes. Whole-blood
DNA samples were genotyped for TCF7L2 single-nucleotide
polymorphisms in conjunction with assessments of 24 week
changes in HbA1c.
Results Linagliptin lowered HbA1c meaningfully in all three
genotypes of rs7903146 (non-risk variant carriers CC
[n=356]: −0.82% [−9.0 mmol/mol], p<0.0001; heterozygous
CT [n=264]: −0.77% [−8.4 mmol/mol], p<0.0001; homozy-
gous risk variant carriers TT [n=73]: −0.57% [−6.2mmol/mol],
p<0.0006). No significant treatment differences were seen
between CC and CT patients, although HbA1c response was
reduced in TT compared with CC patients (~0.26%
[~2.8 mmol/mol], p=0.0182).
Conclusions/interpretation Linagliptin significantly improved
hyperglycaemia in patients with type 2 diabetes both with and
without the TCF7L2 gene diabetes risk alleles. However, dif-
ferences in treatment response were observed, indicating that
diabetes susceptibility genes may be an important contributor
to the inter-individual variability of treatment response.
Keywords Clinical science . DPP-4 inhibitor . Genetics of
type 2 diabetes . Human . Linagliptin . Oral pharmacological
agents . Pharmacogenomics . TCF7L2
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Diabetes is a fast-growing global epidemic with an increasing
prevalence worldwide [1]. Several genes have been associated
with type 2 diabetes susceptibility or manifestation, including
genes encoding receptors, transcription factors, cell cycle-
associated proteins, modifiers of signal transduction, ion chan-
nels and others [2–4]. Recently, single-nucleotide polymor-
phisms (SNPs) of a gene encoding transcription factor 7-like
2 were shown to have the strongest known genetic risk factor
for type 2 diabetes among all diabetes-associated gene SNPs
[5, 6]. The risk of developing diabetes is twice as high in
homozygous TCF7L2 risk variant (rs7903146) carriers (TT)
compared with non-risk carriers (CC) [7, 8]. The initial find-
ings have been replicated in independent studies in multiple
ethnic populations and were summarised in a large global
meta-analysis [5]. Pharmacogenetic studies reported a signifi-
cant association between TCF7L2 risk variants and efficacy of
sulfonylurea treatment, with a twofold greater likelihood of
sulfonylurea treatment failure in TCF7L2 risk carriers [9]. The
mechanisms by which TCF7L2 polymorphisms increase dia-
betes risk and affect the treatment response to insulin secreta-
gogues were thought to be related to impaired incretin-induced
insulin secretion, impaired suppression of glucagon or im-
paired glucagon-like peptide-1 secretion [10–13]. Depending
on the underlying mechanism, the response to other insulin
secretagogues, such as the novel class of dipeptidylpeptidase-4
(DPP-4) inhibitors, also may be affected.
Incretin hormones amplify the first phase of insulin secre-
tion [14]. The advantage of incretin-based therapies, like
orally active DPP-4 inhibitors, is that they have a glucose-
dependent insulinotropic action with no intrinsic risk for caus-
ing hypoglycaemia. Linagliptin, a potent and selective inhib-
itor of DPP-4, improves glucose homeostasis in patients with
diabetes by blocking the degradation of incretins and thus
improving insulin secretion in a glucose-dependent manner
[15, 16]. Linagliptin has been approved for the treatment of
patients with type 2 diabetes [16, 17]. Since linagliptin and the
high-risk polymorphisms of TCF7L2 both affect the same
process responsible for the first phase of insulin secretion, it
can be hypothesised that the response to linagliptin therapy
may differ in patients depending on their allele status. There-
fore, we wanted to explore whether the efficacy response to
linagliptin (i.e. change from baseline in HbA1c or change from
baseline in 2 h postprandial plasma glucose [PPG] after
24 weeks of treatment) is dependent on the TCF7L2 genotype
in a retrospective analysis of clinical data.
Methods
Data sources We conducted analyses of data from four phase
III clinical trials—NCT00601250 [18], NCT00602472
[19], NCT00621140 [20] and NCT00641043 [21]
(www.clinicaltrials.gov)—that evaluated the safety and
efficacy of linagliptin, as monotherapy or in combination
with other glucose-lowering therapy, in improving glycaemic
control in patients with type 2 diabetes (Table 1). Patients were
on stable doses of diabetes medications or, for NCT621140, on
no medications except for linagliptin or placebo. Out of a total
of 2,651 patients randomised to different arms in the four trials,
987 patients gave informed consent for pharmacogenomic
analyses. Both clinical and pharmacogenomic data needed
for the current analyses were available for 961 patients, of
which 693 were treated with linagliptin and 268 received
placebo (Fig. 1). Depending on the trial, patients continued to
receive other glucose-lowering medication in accordance with
the objectives of that trial. Demographic and baseline charac-
teristics of the patients included in these analyses are given in
Table 2.
Clinical objectives The primary clinical endpoint in all four
studies was change in HbA1c (%) from baseline after 24 weeks
of treatment, defined as difference between HbA1c (%) at
24 weeks and HbA1c (%) at baseline. A secondary objective
in studies NCT00601250 [18] and NCT00621140 [20] was
change from baseline in 2 h PPG.
Genotype analysis DNA was extracted from whole-blood
samples and normalised to a standard concentration of
50 ng/μl. In addition, 92 blinded DNA samples from the same
study were used to validate the detected genotypes. Locus-
specific DNA fragments were amplified by PCR with 50 ng
genomic DNA and 5 μmol/l each of forward and reverse
primers. Purified PCR products were sequenced using the
Sanger method [22] in a reaction containing 2 μmol/l se-
quencing primer and BigDye Terminator v3.1 (Life Technol-
ogies, Carlsbad, CA, USA). The sequencing primers were
selected to detect the presence of the following TCF7L2
variants in the sample: rs7903146 (C > T; intron),
rs12255372 (G > T; intron), rs10885406 (A > G; intron) and
rs731788 (C > G; near 3' region microRNA binding site).
Statistical analyses Data were pooled from all randomised
patients from the four trials listed (Table 1) who were treated
with at least one dose of study medication, had baseline
measurements of HbA1c, had at least one measurement of
HbA1c while on treatment, had genetic polymorphism data
available and passed the genetic mismatch quality control
criteria. If the HbA1c data after 24 weeks of treatment were
not available, the last observed data point was carried forward
for the analysis. The homogeneity of the treatment effect on
the primary endpoint change in HbA1c (%) from baseline after
24 weeks in the genotype subgroups was investigated using an
ANCOVA. Baseline HbA1c was the linear covariate, while
washout period for prior oral glucose-lowering therapy
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(yes/no), treatment-genotype group (genotype groups CC, CT
and TT for patients treated with linagliptin and the placebo
group), race and study were set as fixed classification effects.
Pairwise comparisons between homozygous non-risk (CC)
and heterozygous risk (CT) or homozygous risk (TT) variant
carriers receiving linagliptin as monotherapy or in combina-
tion with other anti-hyperglycaemic agents were also
performed. To evaluate how representative the subgroup of
patients with available pharmacogenomic data was with re-
spect to their response to linagliptin therapy, the results ob-
tained from these analyses were compared with those from the
corresponding ANCOVA analyses on the pooled clinical data
from all patients in the four studies. Demographic variables
and baseline characteristics of the genotyped subpopulation
were tested for differences between treatment–genotype
groups (genotype groups CC, CT and TT for patients receiv-
ing linagliptin, and the placebo group) by χ2 test, Fisher’s
exact test or ANOVA.
Additional analyses were performed to address the poten-
tial influence of study, demographic and baseline characteris-
tics by subgroup analyses as well as by incorporating them as
additional factors or covariates into the ANCOVA model.
Sensitivity analysis to investigate the impact of the last obser-
vation carried forward (LOCF) imputation was performed
using only observed cases. SAS version 9.2 (SAS Institute,
Cary, NC, USA) was used for all analyses.
Results
Demographic and baseline characteristics Demographic var-
iables and baseline characteristics were tested for differences
between treatment–genotype groups (genotype groups CC,
CT and TT for patients receiving linagliptin, and the placebo
group). A significant difference was observed only for race
Table 1 Details of studies from which data were extracted for retrospective analyses
Study detail NCT00601250 [18] NCT00602472 [19] NCT00621140 [20] NCT00641043 [21]
Intervention Once daily oral
linagliptin 5 mg
Once daily oral linagliptin 5 mg Once daily oral
linagliptin 5 mg
Once daily oral linagliptin 5 mg
Co-medication Metformin ≥ 1,500 mg/day Metformin ≥ 1,500 mg/day +
sulfonylurea at maximum
tolerated dose
None Once daily pioglitazone 30 mg





24 weeks of treatment
Efficacy and safety of linagliptin
compared with placebo add-on
therapy to metformin in
combination with a
sulfonylurea background
therapy after 24 weeks
of treatment
Efficacy and safety of
linagliptin monotherapy
compared with placebo
after 24 weeks of
treatment
Efficacy and safety of linagliptin
in combination with pioglitazone
30 mg, compared with
pioglitazone 30 mg monotherapy
after 24 weeks of treatment
Failed quality control
• DNA quality, n=6




Quality clinical and genomic data available
n=961
Informed consent for genomic analysis
n=987








Fig. 1 Sample selection for
analyses of TCF7L2 SNPs with
clinical outcome
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(p<0.0001) due to different frequencies of the TCF7L2 risk
allele in different ethnicities (see Table 3), so race was includ-
ed into the ANCOVA model. The observed slight differences
for baseline weight (p=0.0443) and BMI (p=0.0518) had no
influence on the results when including them additionally into
the ANCOVA model.
Distribution of allelic and genotype frequencies The allelic
and genotype frequencies of the various TCF7L2 polymor-
phisms were determined for the cohort of consenting patients
and the data categorised by race. The data for SNP rs7903146,
which has the strongest association with type 2 diabetes, are
shown in Table 3. The minor allelic frequency for the T allele
was highest among white patients (34.3%) and lowest among
Asian patients (18.5%), with black patients falling in the
middle (20.0%). Homozygous TToccurred in 12.1% of white
and 6.0% of Asian patients, but was absent in the black
patients (Table 3), possibly owing to the low number of black
patients participating in these studies. The observed frequen-
cies in the white and Asian patients are concordant with
publicly available allele and genotype frequencies [23, 24].
Results for the other polymorphisms and haplotypes were
similar to those for rs7903146 (data not shown).
Comparison of clinical response between genotyped subgroup
and all patients To determine whether the subgroup for which
genomic analysis was performed was representative of the
population of patients who participated in all four trials, the
clinical response observed for the subgroup was compared
with that of the whole patient population (Fig. 2). The clinical
responses to treatment with linagliptin or placebo in the sub-
groups for which pharmacogenomic data were available were
essentially identical to those of the corresponding treatment
groups in the whole cohort of patients from the four clinical
trials—reduction in HbA1c was similar in the two groups
treated with linagliptin and HbA1c did not change from
Table 2 Demographic and baseline characteristics
Characteristic Placebo Linagliptin Total
CC CT TT
Number of patients 268 356 264 73 961
Sex, n (%)
Male 132 (49.3) 170 (47.8) 121 (45.8) 45 (61.6) 468 (48.7)
Female 136 (50.7) 186 (52.2) 143 (54.2) 28 (38.4) 493 (51.3)
Race, n (%)
White 185 (69.0) 205 (57.6) 205 (77.7) 59 (80.8) 654 (68.1)
Black 1 (0.4) 3 (0.8) 1 (0.4) 0 (0.0) 5 (0.5)
Asian 82 (30.6) 148 (41.6) 58 (22.0) 14 (19.2) 302 (31.4)
Mean age, years (SD) 56.7 (10.1) 57.5 (9.7) 57.3 (10.1) 58.7 (9.4) 57.3 (9.9)
Age groups, years, n (%)
≤50 71 (26.5) 75 (21.1) 68 (25.8) 14 (19.2) 228 (23.7)
51 to <65 135 (50.4) 196 (55.1) 125 (47.3) 41 (56.2) 497 (51.7)
65 to <75 55 (20.5) 72 (20.2) 65 (24.6) 14 (19.2) 206 (21.4)
≥75 7 (2.6) 13 (3.7) 6 (2.3) 4 (5.5) 30 (3.1)
Mean baseline weight, kg (SD) 80.71 (16.74) 78.19 (17.82) 81.37 (16.19) 82.83 (17.64) 80.12 (17.12)
Mean baseline BMI, kg/m2 (SD) 29.74 (4.75) 29.09 (5.10) 30.12 (4.65) 29.12 (4.71) 29.56 (4.86)
Baseline BMI categorical, kg/m2, n (%)
<25 47 (17.5) 84 (23.6) 40 (15.2) 14 (19.2) 185 (19.3)
25 to <30 103 (38.4) 132 (37.1) 95 (36.0) 30 (41.1) 360 (37.5)
≥30 118 (44.0) 140 (39.3) 129 (48.9) 29 (39.7) 416 (43.3)
Mean baseline HbA1c, % (SD) 8.2 (0.9) 8.2 (0.8) 8.2 (0.8) 8.1 (0.9) 8.2 (0.9)
Mean baseline HbA1c, mmol/mol (SD) 66.1 (9.8) 66.1 (8.7) 66.1 (8.7) 65.0 (9.8) 66.1 (9.8)
Baseline HbA1c, categorical %, n (%)
<7.0 12 (4.5) 17 (4.8) 13 (4.9) 2 (2.7) 44 (4.6)
7.0 to <8.0 106 (39.6) 146 (41.0) 96 (36.4) 34 (46.6) 382 (39.8)
8.0 to <9.0 93 (34.7) 124 (34.8) 106 (40.2) 24 (32.9) 347 (36.1)
≥9.0 57 (21.3) 69 (19.4) 49 (18.6) 13 (17.8) 188 (19.6)
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baseline in the two groups receiving placebo. These results
suggest that the pharmacogenomic subgroups were represen-
tative of the entire pooled patient population.
Subgroup analyses To address possible differences between
the trials, we analysed each trial separately as well as in a
pooled analysis again, incorporating additionally the study-
by-treatment–genotype group interaction effect in the
ANCOVA model. No significant heterogeneity of effects
across the trials was observed. Detailed information and re-
sults of ANCOVA for each specific trial in comparison to the
whole study population are given in electronic supplementary
material (ESM) Table 1.
Association of genotype with clinical response Based on
TCF7L2 rs7903146 genotype, patients receiving linagliptin
therapy were categorised into three groups: CC (homozygous
non-risk allele carrier), CT (heterozygous) and TT (homozygous
risk allele carrier). The strongest, almost identical, response to
linagliptin therapy (i.e. lowering of HbA1c) was observed in
patients with homozygous CC (n=356; p<0.0001) and hetero-
zygous CT (n=264; p<0.0001) genotypes with a decrease of
0.82% (9.0 mmol/mol) and 0.77% (8.4 mmol/mol) in HbA1c,
respectively, compared with baseline (Fig. 3). A less robust, but
still statistically (p=0.0006) and clinically significant, decrease
of 0.57% (6.2 mmol/mol) in HbA1c in response to linagliptin
therapy after 24 weeks was observed in patients who were
homozygous TT (n=73). The difference in response to
linagliptin therapy between homozygous TT patients and ho-
mozygous CC patients was statistically significant (p=0.0182).
The comparison of the number of patients in LOCF anal-
yses vs the number of patients with observed 24 week data
indicate that we have >80% observed cases in the linagliptin-
treated group and >70% in the placebo group. The results,
based only on observed cases, showed a significant difference
of ~0.23% (p=0.0392) between linagliptin-treated homozy-
gous TT and non-risk-carrier CC patients and this is in con-
cordance with the results obtained in the analyses for the
LOCF set.
Association of genotype with PPG levels Patients receiving
placebo showed an increase from baseline in 2 h PPG levels
with a mean rise of 2.13 mmol/l (ESM Fig. 1), which is likely
related to the washout of previous glucose-lowering agents
in the two clinical studies NCT00601250 [18] and
NCT00621140 [20]. This was in accordance with an increase
in HbA1c levels in the placebo group in those two studies.
Similar to the observed HbA1c levels after treatment, all
Table 3 Allelic and genomic
frequencies of TCF7L2
rs7903146 polymorphisms in the
analysed population
Race n Minor allele
frequency (%)
Genotype frequency (%) Test for deviation
from Hardy–Weinberg
equilibrium (p value)T CC CT TT
Asian 302 18.5 68.9 25.2 6.0 0.0037
Black 5 20.0 60.0 40.0 0.0 0.5762
White 654 34.3 43.4 44.5 12.1 0.7371
All races 961 29.3 51.5 38.4 10.1 0.0235

























Fig. 2 Adjusted mean difference between HbA1c (%) at a given time and
HbA1c (%) at baseline (change in HbA1c [%] from baseline) with 95%
CIs for the whole cohort of patients from the four clinical trials and the
subgroup for which pharmacogenomic data were available. ANCOVA
model includes baseline HbA1c as linear covariate and prior oral glucose-
lowering therapy (yes/no), treatment, study and treatment-by-study inter-
action as fixed classification effects. Placebo complete clinical data,
n=728; placebo genotyped subgroup, n=268; linagliptin complete clin-
ical data, n=1,876; linagliptin genotyped subgroup, n=693. Black trian-
gles, placebo complete clinical data; white triangles, placebo genotyped
subgroup; black circles, linagliptin complete clinical data; white circles,
linagliptin genotyped subgroup. To convert values for HbA1c in DCCT%



































Fig. 3 TCF7L2 rs7903146 genotype-associated adjusted mean differ-
ence between HbA1c (%) at a given time and HbA1c (%) at baseline
(change in HbA1c [%] from baseline) with 95% CIs. Linagliptin CC,
n=356; linagliptin CT, n=264; linagliptin TT, n=73; placebo, n=268.
****p<0.0001 vs placebo at 24 weeks; †p<0.05, linagliptin-treated
homozygous CC vs homozygous TT patients at 24 weeks. Black circles,
linagliptin CC; black squares, linagliptin CT; white circles, linagliptin TT;
black triangles, placebo. To convert values for HbA1c in DCCT % to
mmol/mol, multiply by 10.929 and then subtract 23.50
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patients treated with linagliptin showed a decrease from base-
line in 2 h PPG levels after 24weeks. Patients homozygous for
the wild-type allele (CC) showed the greatest decrease from
baseline in 2 h PPG levels, with a mean decrease of
2.78mmol/l. Although there was greater variability in patients
heterozygous for the risk allele (CT), the reduction from
baseline in 2 h PPG levels was similar to that observed in
the homozygous CC patients, with a mean decrease of
2.55 mmol/l. Patients homozygous for the risk allele (TT)
showed the smallest decrease from baseline in 2 h PPG levels
(1.65 mmol/l), although it should be noted that only a few
patients’ data (n=6) was available for this group.
Discussion
The present studies have been undertaken to assess the impact
of TCF7L2 genotypes on the response to incretin-based ther-
apy, for the first time in a longitudinal setting. This is impor-
tant because genetic polymorphism has been suggested to
contribute to the susceptibility of individuals to environmental
stimuli, resulting in increased prevalence of diabetes. Of the
many genes investigated, TCF7L2, a β-catenin bipartite tran-
scription factor, integral to the upregulation of incretin secre-
tion from intestinal endocrine L cells and the proliferation of
pancreatic beta cells [25–27], has the strongest known asso-
ciation with diabetes [5, 6]. The high-risk genotypes of
TCF7L2 SNPs rs7903146 and rs12255372 are strongly asso-
ciated with reduced insulin secretion, possibly owing to im-
paired response to incretins [10, 11] and impaired beta cell
function [10, 12, 13]. Accordingly, we tested the hypothesis
that the efficacy response to linagliptin therapy, which acts via
inhibition of incretin degradation, may be reduced in patients
with type 2 diabetes who have high-risk TCF7L2 genotypes. It
is possible that these individuals may be genetically
predisposed to produce and secrete less incretin or have an
impaired incretin response compared with those with
wild-type genotype.
As expected, in the pooled analyses, the HbA1c levels of
patients showed no change from baseline when administered
placebo. In response to treatment with linagliptin, wild-type ho-
mozygous patients exhibited a robust −0.82% (−9.0 mmol/mol)
reduction from baseline in HbA1c levels (p<0.0001). In
contrast, the response to treatment with linagliptin in patients
who were homozygous for the risk allele was reduced
(−0.57% [−6.2 mmol/mol] decrease from baseline in HbA1c
on average; p<0.0006), but still clinically meaningful
(>0.5% [>5.5 mmol/mol] decrease).
Similar to the observations for HbA1c, homozygous
wild-type patients treated with linagliptin showed a decrease
in 2 h PPG levels compared with patients receiving placebo.
Heterozygous patients exhibited a response similar to that
observed for homozygous wild-type patients and homozygous
risk carriers (TT) showed the least decrease from baseline in
2 h PPG levels. However, the number of patients in each of
these groups was small and probably not sufficient to allow
meaningful conclusions to be made.
The observed differences in linagliptin efficacy response of
~25% between TCF7L2 homozygous risk carriers (12% of
whites) and non-risk carriers are in line with previous data of
an association of TCF7L2 and sulfonylurea response [9]. This
would support the recent postulation by Schäfer et al [28] that
TCF7L2 variants are associated with a functional defect in the
beta cells. Considering that the efficacy response to linagliptin
in the TT carriers was clinically relevant, it is intriguing to
speculate that a stronger loss of efficacy than that observed in
this investigation would have been expected in homozygous
carriers if a specific incretin-related defect was present. Based
on present data, this cannot be ruled out. Another possibility
for the lack of a more pronounced effect may be that poly-
morphisms in a single gene may not be sufficient to produce a
significant change in a patient’s response to a DPP-4 inhibitor.
Variants in additional genes could potentially contribute to
inter-individual variability in response, and combined analy-
ses of several risk genes for type 2 diabetes implicated in the
regulation of beta cell function may further help explain the
variability of efficacy response to insulin secretagogues.
The study has some limitations, mainly related to the
relatively small sample size. This was addressed by combin-
ing the data from four clinical trials. However, we cannot
completely rule out the influence of co-medication. The fact
that we did observe the same trend for the differences in
response to linagliptin treatment between CC wild-type and
TT risk carriers by analysing each trial with different back-
ground therapies separately, supports our hypothesis. In addi-
tion, a disease–genetic process in TCF7L2 carriers could
contribute to the effect, but the change in HbA1c level from
baseline in the placebo groups did not reveal differences
between CC and TT risk allele carriers, indicating a pharma-
cogenetic effect.
Nevertheless, results must be interpreted with some caution
and should ideally be confirmed in a second cohort. Since
linagliptin was the only DPP-4 inhibitor evaluated, it is
unknown whether or not these observations are specific
to linagliptin or whether they can be regarded as a class
effect.
In conclusion, to our knowledge, these are the first studies
testing the impact of TCF7L2 genotype on the response to
incretin therapy (DPP-4 inhibitor) in a longitudinal cohort.
Our analyses demonstrate for the first time that although the
clinical response to the DPP-4 inhibitor linagliptin was
somewhat attenuated in homozygous TCF7L2 risk car-
riers, this treatment results in a clinically meaningful glucose-
lowering potency, even in homozygous high-risk allele carrier
patients.
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